ME
MESO.US Mesoblast Ltd
- Market cap
- USD 1.72B
- P/E
- -
- P/B
- 3.03x
- ROE
- -6.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is MESO.US undervalued?
Graham numberThe Graham number of Mesoblast Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mesoblast Ltd fundamental analysis
No fundamental analysis for Mesoblast Ltd yet.
Mesoblast Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as we…
Full company profileMesoblast Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mesoblast Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.41M | 17.3M | 16.7M | 32.2M | 7.46M | 10.2M | 7.50M | 5.90M | 17.2M | 121M | 140M |
| Gross Profit | -9.65M | 11.8M | -58.5M | -49.3M | -78.3M | -53.4M | -47.4M | -35.2M | 12.1M | 102M | 197M |
| Operating Income | -90.0M | -77.3M | -80.2M | -74.9M | -109M | -80.6M | -69.3M | -84.1M | -62.4M | -51.5M | -82.0M |
| EBITDA | -87.2M | -74.7M | -84.5M | -69.0M | -84.7M | -76.6M | -58.6M | -53.3M | -73.7M | -42.9M | -37.3M |
| Net Income | -76.8M | -35.3M | -89.8M | -77.9M | -98.8M | -91.3M | -81.9M | -88.0M | -102M | -57.8M | -34.7M |
| EPS | -1.43 | -0.38 | -1.82 | -1.47 | -1.63 | -1.34 | -0.98 | -0.89 | -0.85 | -0.45 | -0.27 |
| Balance Sheet | |||||||||||
| Total Assets | 656M | 692M | 652M | 734M | 745M | 662M | 669M | 669M | 785M | 773M | 773M |
| Total Liabilities | 139M | 146M | 171M | 184M | 163M | 165M | 168M | 189M | 187M | 205M | 205M |
| Shareholders' Equity | 517M | 546M | 481M | 549M | 581M | 497M | 502M | 480M | 597M | 568M | 568M |
| Cash & Short-term Investments | 45.8M | 37.8M | 50.4M | 129M | 137M | 60.0M | 70.9M | 62.6M | 161M | 47.4M | 103M |
| Total Debt | - | 59.4M | 81.3M | 99.3M | 105M | 107M | 116M | 119M | 128M | 127M | 127M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -95.5M | -75.0M | -57.8M | -56.4M | -107M | -65.8M | -63.3M | -48.5M | -50.0M | -43.8M | -8.51M |
| Capital Expenditure | 311K | 201K | 279K | 2.25M | 1.65M | 232K | 314K | 331K | 730K | 898K | 1.31M |
| Free Cash Flow | -95.8M | -75.2M | -58.1M | -58.6M | -108M | -66.0M | -63.6M | -48.8M | -50.7M | -44.7M | -9.82M |
| Ratios | |||||||||||
| ROE | -14.9% | -6.5% | -18.7% | -14.2% | -17.0% | -18.4% | -16.3% | -18.3% | -17.1% | -10.2% | -6.1% |
| ROA | -11.7% | -5.1% | -13.8% | -10.6% | -13.3% | -13.8% | -12.2% | -13.1% | -13.0% | -7.5% | -4.5% |
| Net Profit Margin | -3,184.7% | -203.5% | -537.0% | -242.4% | -1,325.3% | -894.6% | -1,091.7% | -1,490.3% | -593.9% | -47.8% | -24.8% |
| Debt to Equity | - | 0.11x | 0.17x | 0.18x | 0.18x | 0.22x | 0.23x | 0.25x | 0.21x | 0.22x | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mesoblast Ltd dividends
Mesoblast Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:2 on Jan 10, 2024.
Who owns Mesoblast Ltd
- Insiders 57.34%
- Institutions 3.38%
- Public & others 39.29%
- Shares outstanding 130M
- Free float 83.2M
Top funds holding MESO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Biotechnology ETF | 573K | 0.44% | -0.19% | Oct 2026 |
| UTM IM GBP AXA Framlington Biotech | 260K | 0.20% | 0.00% | Sep 2026 |
| M&G Recovery GBP A Acc | 59.1K | 0.05% | 0.00% | Jul 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 44.9K | 0.03% | +0.20% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 14.1K | 0.01% | -58.19% | Aug 2026 |
| ActivePassive International Equity ETF | 11.5K | 0.01% | 0.00% | Oct 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 8.32K | 0.01% | +4.09% | Jun 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 7.03K | 0.01% | +1.93% | Oct 2026 |
| Steward Values Enhanced International I | 6.51K | 0.01% | 0.00% | Sep 2026 |
| Invesco Nasdaq Biotechnology ETF | 4.06K | 0.00% | 0.00% | Oct 2026 |
| ProShares Ultra Nasdaq Biotechnology | 2.09K | 0.00% | 0.00% | Oct 2026 |
| Xtrackers MSCI Genomic HC Inno ETF 1C | 1.95K | 0.00% | +16.07% | Sep 2026 |
| GF NASDAQ Bio-Tech Idx QDII USD A | 1.11K | 0.00% | +15.04% | Jun 2026 |
| Dimensional Glbl ex US CorEqMktETFUSDAcc | 18.00 | 0.00% | 0.00% | Oct 2026 |
| Global Core Equity UCITS ETF USD Acc | 12.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding MESO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 719K | 0.55% | +39.69% | Jun 2026 |
| BlackRock Inc | 664K | 0.51% | +5.30% | Jun 2026 |
| Susquehanna International Group, LLP | 458K | 0.35% | +18.44% | Jun 2026 |
| The Goldman Sachs Group Inc | 396K | 0.30% | -0.40% | Jun 2026 |
| BNP Paribas Investment Partners SA | 260K | 0.20% | 0.00% | Jun 2026 |
| UBS Group AG | 200K | 0.15% | +50.90% | Jun 2026 |
| SRS Capital Advisors Inc | 168K | 0.13% | +587.91% | Jun 2026 |
| Bank of America Corp | 100K | 0.08% | 0.00% | Jun 2026 |
| Penbrook Management LLC | 87.1K | 0.07% | 0.00% | Jun 2026 |
| M&G PLC | 59.1K | 0.05% | 0.00% | Jun 2026 |
| Quadrature Capital Limited | 53.1K | 0.04% | +208.03% | Jun 2026 |
| LPL Financial Corp | 47.9K | 0.04% | -3.53% | Jun 2026 |
| Rialto Wealth Management, LLC | 46.5K | 0.04% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 44.0K | 0.03% | -47.53% | Jun 2026 |
| Royal Bank of Canada | 44.0K | 0.03% | +67.53% | Jun 2026 |
| Two Sigma Investments LLC | 43.4K | 0.03% | +9.05% | Jun 2026 |
| Geode Capital Management, LLC | 33.7K | 0.03% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 33.2K | 0.03% | -66.44% | Jun 2026 |
| Wiley Bros.-Aintree Capital, LLC | 27.6K | 0.02% | +2.30% | Jun 2026 |
| Citigroup Inc | 26.2K | 0.02% | -0.88% | Jun 2026 |
Mesoblast Ltd company profile
- Company name
- Mesoblast Ltd
- Ticker
- MESO.US
- Exchange
- USA Stocks
- Listed since
- Nov 13, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 108
- Fiscal year end
- June
- Address
- 55 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9639 6036
- Website
- mesoblast.com
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Mesoblast Ltd management
10- Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director · born 1957
- Mr. James Michael O'Brien CPA, M.B.A.Chief Financial Officer · born 1966
- Mr. Paul Hughes BPHARMGlobal Head of Corporate Communications & Joint Company Secretary
- Mr. Anthony WhealHead of Human Resources
- Dr. Paul J. Simmons BSc, Ph.D.Scientific Advisor to the Chief Executive Officer · born 1959
- Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality Management
- Mr. Daniel Devine B.Sc., J.D., M.B.AHead of Special Projects
- Mr. Justin Horst B.S.Head of Manufacturing
- Dr. Fiona See Ph.D.Senior VP & Head of Translational Research
- Mr. Marcelo SantoroChief Commercial Officer